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1. Introduction 
Targeted therapy is a strategy of anticancer treatment that aims to interfere with processes 
of tumorigenesis, cancer progression and metastasis by selectively affecting key molecules 
of tumor cells (Armand et al., 2007; Favoni & Florio, 2011; Gross-Goupil & Escudier, 2010). 
Targeted therapies are directed to small molecules participating in different mechanisms 
that control cell survival through cellular proteins or signalling pathways (Mueller et al., 
2009; Zahorowska et al., 2009). Targeted therapies may offer enhanced efficacy, enhanced 
selectivity, and less toxicity. However, targeting selective molecules and pathways often 
induces the activation of redundant mechanisms and enhances the emergence of resistant 
cells due to selective pressure (Woodcock et al., 2011). This is one of the reasons why the 
effects of targeted agents are not durable when used alone, and often result in drug 
resistance and clinical relapse.  
Except for specific cases the use of these targeted drugs as monotherapy is often 
discouraged due to lack of efficacy. However, combined therapy with drugs targeting 
several mechanisms of tumor cell death can greatly improve efficacy and may overcome 
resistance. Several genomic and epigenetic alterations have been identified in tumor cells 
that lead to unrestrained proliferation, evasion of proapoptotic signals, metastasis, and 
resistance to drug-induced cell death. These alterations are critical for cancer progression 
and therefore combination strategies employing multiple targeted agents can be a successful 
therapeutic strategy. In vertical combination strategies two or more drugs target a same 
pathway at two different points, while in horizontal combinations drugs are directed 
towards different intracellular signalling pathways and have the potential advantage of 
combining agents with non-overlapping toxicities (Gross-Goupil & Escudier, 2010).  
Novel treatments require the investigation of mechanisms of action and synergy of 
combination treatments to enhance the role of the targeted pharmacological agents (Carew 
et al., 2008; Mitsiades et al., 2011). Evaluating combinations of targeted drugs, including 
investigational agents, are an essential part of this effort (Dancey & Chen, 2006). An 
interesting example is represented by Bortezomib, a drug currently effective as single agent 
in multiple myeloma and mantle cell lymphoma (Bross et al., 2004; Kane et al., 2007; Wright, 
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2010). Bortezomib is a proteasome inhibitor that selectively triggers apoptosis in various 
types of neoplastic cells. It has been tested in a wide variety of solid tumors but has 
generally been ineffective as monotherapy (Boccadoro et al., 2005). However Bortezomib has 
shown increased activity when combined with several novel targeted agents including 
protein deacetylase inhibitors, kinase inhibitors, farnesyltransferase inhibitors, HSP-90 
inhibitors, pan-Bcl-2 family inhibitors, and other classes of targeted inhibitors (Dai et al., 
2003; Karp & Lancet, 2005; Pei et al., 2004; Perez-Galan et al., 2008; Trudel et al., 2007; 
Workman et al., 2007; Yanamandra et al., 2006). Thus, Bortezomib in combination with 
novel targeted therapies increase antitumor activity and overcome specific cellular 
antiapoptotic mechanisms (Wright, 2010). 
Two-drug combination therapies are being assessed in a variety of tumors, usually testing 
agents that have different targets, nonoverlapping toxicity, and some rationale for 
evaluation (Belinsky et al., 2011; Castaneda & Gomez, 2009; Eriksen et al., 2009; Klosowska-
Wardega et al., 2010). An increase in the number of these studies is expected in coming 
years, on the basis of emerging data with new agents, which is expanding our 
understanding of the molecular pathways important in cancer progression. (Woodcock et 
al., 2011). Tumor intracellular signalling pathway dependencies are being increasingly 
analyzed, and patients treated on the basis of resistance profile detected for specific drug 
combinations (Busch et al.; Derenzini et al., 2009; Michiels et al., 2011). This approach may 
facilitate the development of combination regimens optimized for specific tumor subtypes, 
thus providing the potential for tailored therapy in individual patients on the basis of 
certain molecular and genetic characteristics of their disease.  
1.1 Targeted drugs often induce programmed cell death as their main mechanism of 
anti-tumor activity 
Many of the classic chemotherapeutic agents (alkylating agents, antimetabolites, antibiotics, 
topoisomerase inhibitors) are known to block cell division by compromising DNA 
replication and halting cell cycle progression, or inhibit mitosis, eventually leading to cell 
death (Foye, 1995; Goodman et al., 2010; Shuck & Turchi, 2010). Indicators of cell proliferation 
are suitable effect biomarkers to assess whether a combination of these agents is synergic, 
additive or antagonistic. Biomarkers frequently used for this purpose include incorporation 
of nucleotide analogues such as bromodeoxyuridine, or metabolic indicators of cell number 
such as tetrazolium salt-based assays (Karaca et al., 2009; Olszewska-Slonina et al., 2004; 
Sims & Plattner, 2009). However many of the new targeted agents interfere with 
constitutively active survival pathways or initiate apoptosis by directly influencing pro-
apoptotic signals (Citri et al., 2004; Kim et al., 2005; Larsen et al., 2011; Vega et al., 2009; 
Zhang et al., 2009). In addition autophagic cell death and programmed necrosis are being 
actively investigated as alternative and pharmacologically relevant forms of programmed 
cell death (Berghe et al., 2010; Bijnsdorp et al., 2011; Duan et al., 2010; Gozuacik & Kimchi, 
2007; McCall, 2010; Notte et al., 2011; Paglin et al., 2005; Platini et al., 2010). Combination 
studies should be conducted using effect biomarkers that are as close as possible to the 
known mechanisms targeted by single agents, and biomarkers specifically related to drug-
induce tumor cell death appear more adequate for the assessment of new targeted agents 
(Cameron et al., 2001; Facoetti et al., 2008; Wesierska-Gadek et al., 2005). A straightforward 
approach is to determine the proportion of live and dead cells in viability studies scoring 
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thousands of cells through flow cytometry which ensures exceptional precision for dose-
effect cytotoxicity studies.  
2. Assessment of viability through flow cytometry 
The strength of flow cytometry when compared to other methods available to assess the 
proportion of live and dead cells is the accuracy and precision brought by single cell 
multiparametric assessment. A variety of fluorescent probes may be chosen to use in 
viability assessment through flow cytometry. These probes are based on cell functions and 
biological conditions that are differentially preserved in live cells and lost in dead cells. It is 
usual to select at least two probes measuring independent functional conditions. For 
example, a probe evaluating membrane integrity of cells and another probe evaluating 
enzymatic activity. Probes should be selected to match specific experimental requirements 
such as biological variability, duration of the experiments, whether cells exposed to drugs 
are adherent or non-adherent, and illumination lines available in the flow cytometer. Some 
probes may be released after being retained within the cells for a short time and require 
immediate assessment through the flow cytometer after labelling, while others may be 
retained for several hours or may be even retained indefinitely by being covalently linked to 
cellular components. In addition some specimens may require fixation due to biohazard 
issues, so another kind of probes should be chosen and combined in these cases (De Clerck 
et al., 1994).  
2.1 Fluorescent staining of live and dead cells 
Viability is not easily defined in terms of a single physiological or morphological parameter. 
No single parameter fully defines cell death in all systems; therefore, it is often 
advantageous to use more than one cell death indicators based on different parameters such 
as membrane damage, and enzymatic or metabolic activity. A considerably large number of 
fluorescent probes have been introduced in the recent years that are dedicated to the 
assessment of viability on a single cell basis. Many of these new probes have features that 
are useful under specific experimental circumstances. The two conditions most often 
detected are increased cell membrane permeability in dead cells and the presence of 
enzymatic activity in live cells. The former is assessed with probes that become fluorescent 
when bound to DNA but are not able to pass through cell membrane if selective 
permeability is preserved, while the later is determined by fluorogenic substrates. However 
other conditions occurring only in live cells may be used to demonstrate viability such as 
enzymatic oxidation, reduction and mitochondrial membrane potential (Callewaert et al., 
1991). It is important to underscore this concept because these probes are often used for 
assessment of specific cellular functions and it may be erroneously assumed that they have 
no contribution to the assessment of viability. 
2.2 Enzymatic activity in live cells, use of tracker dyes 
One of the first probes introduced and most frequently used to stain live cells has been 
fluorescein-diacetate (FDA) (Jones & Senft, 1985; Ross et al., 1989). This non-fluorescent cell-
permeant esterase substrate penetrates the cell and is converted by nonspecific intracellular 
esterases into fluorescein.  
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Thus it becomes a more polar compound and is retained within those cells that have intact 
plasma membranes. In contrast, nonfluorescent FDA and fluorescein rapidly leak from 
those cells that have a damaged cell membrane because it is no longer retained due to 
increased permeability (Prosperi et al., 1986). This property ensures that dead cells will 
never retain FDA or fluorescein, even if cell death occurs after the labelling procedure. This 
is one of the reasons why it is recommended to analyze cells rapidly through the flow 
cytometer after staining with FDA and why they should be kept in low incubation 
temperatures to minimize potential fluorescein leakage.  
Calcein-acetoxymethyl-ester (Calcein-AM) is a derivative of calcein that has several 
improvements over FDA (Duan et al., 2010; Papadopoulos et al., 1994). Calcein-AM is also a 
substrate of nonspecific intracellular esterases. The fluorescent product is calcein and is 
better retained in cells because it is a polyanionic compound that has six negative charges 
and two positive charges at pH 7. Calcein-Blue-AM and Calcein-Violet-AM are similar to 
Calcein-AM but have different excitation and emission wavelengths (Fuchs et al., 2007). 
Calcein-Blue-AM is excited with UV lasers while Calcein-Violet-AM is excited with 405 nm 
violet diode lasers, although both dyes emit blue fluorescence (Prowse et al., 2009). They can 
be used when the green fluorescence channel from the 488 nm excitation line is needed for 
other purpose and a UV or violet illumination line is available. Chloromethyl-fluorescein-
diacteate (CM-FDA), is a FDA derivative that is retained within the cell even after damage 
to the plasma membrane due to its ability to bind thiol groups (Lantz et al., 2001; Sarkar et 
al., 2009). The weakly thiol-reactive chloromethyl moieties of this compound react with 
intracellular thiols and the acetate groups are cleaved by cytoplasmic esterases (West et al., 
2001). This compound will not stain dead cells but the label will be preserved in those cells 
that die after the labelling procedure because the fluorescent product will be bound to SH 
groups within the cells (Sebastia et al., 2003). Chloromethyl SNARF-1 acetate is similar to 
CM-FDA but exhibits red fluorescence when excited with 488 nm blue laser. Thus it can be 
used when the green fluorescence channel is needed for other purpose and a UV or violet 
illumination line is not available (Hamilton et al., 2007). Carboxi-fluorescein-succinimidyl-
ester (CFSE) is converted to fluorescent compound by intracellular esterases but covalently  
ExcellentGreenBlueCFSE
ExcellentOrangeBlue5-Cl-M-SNARF
ExcellentGreenBlue5-Cl-M-FDA
GoodBlueVioletCalcein Violet-
AM
GoodBlueUVCalcein Blue-AM
GoodGreenBlueCalcein-AM
PoorGreenBlueFDA
Intracellular 
retention
Fluorescence 
emission
Excitation
line
Probe
 
Table 1. Fluorogenic substrates of intracellular esterases that are commonly used as viability 
probes  
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binds amino groups of proteins and is completely retained within cells, even after damage 
of cell membrane (Fujioka et al., 1994; Li et al., 2003). This dye is also used as cell tracker 
because it is retained in daughter cells after several rounds of cell division (Parish & Warren, 
2002). It is worth to note that probes like FDA may give poor results with trypsinized cells 
owing to potential leakage of fluorescein during the staining and washing procedures 
(Zamai et al., 2001). Thus probes like CM-FDA, CM-SNARF-1, and CFSE may be a better 
choice for staining adherent cells. 
2.3 DNA labelling in live and dead cells 
Many polar nucleic acid stains are able to enter eukaryotic cells only when the plasma 
membrane is damaged. These stains are known as cell-impermeant dyes and include 
propidium iodide (PI) which is the most frequently used probe for assessing viability in 
flow cytometry (Yeh et al., 1981). This dye is excluded from live cells because it is negatively 
charged but readily penetrates the membrane of damaged cells and binds DNA. When 
excited at 488 nm DNA-bound PI increases orange-red fluorescence emission more than 
1000 fold. Another commonly used cell-impermeant dye excited with 488 nm laser is  
7-aminoactinomycin-D (7AAD). This dye binds DNA only in dead cells but emits 
fluorescence beyond 610 nm and allows the usage of the yellow-orange fluorescence channel 
for other purpose (Pallis et al., 1999). 
Both PI and 7AAD have large Stokes shifts and can be used in 488 nm laser flow cytometers 
with green fluorescent tracker dyes such as FDA, CM-FDA, Calcein-AM and CFSE. Cells 
with damaged membranes may be identified with other cell-impermeant DNA fluorescent 
dyes that emit fluorescence in different wavelengths than that of PI.  
The SYTOX series includes SYTOX-green (excited with 488 nm laser), SYTOX-red (excited 
with 633 and 635 nm lasers) and SYTOX-blue (excited with UV or 405 nm violet diode laser) 
(Haase, 2004; Lebaron et al., 1998; Yan et al., 2005). In contrast to SYTOX dyes, the SYTO 
series of nucleic acid stains can enter live cells and are thus cell-permeant DNA dyes (Ullal 
et al., 2010). The SYTO probes bind DNA with low affinity in live or dead cells (Eray et al., 
2001; Poot et al., 1997). They are combined with high affinity cell-impermeant dyes to 
discriminate live from dead cells (Wlodkowic & Skommer, 2007). For example cell-permeant 
SYTO-red will stain live and dead cells with red fluorescence binding with low affinity to 
DNA, but if used together with SYTOX-green dead cells will be green fluorescent, because 
SYTOX-green has much higher affinity for DNA and will displace the low affinity SYTO-
red. In addition, SYTOX-green will never stain live cells because it is cell-impermeant. 
2.4 Biohazardous specimens 
Viability staining of biohazardous specimens often requires fixation procedures that 
inactivate pathogens but produce minimal distortion of cellular characteristics. Some 
combinations of cell permeant and cell impermeant DNA dyes can be treated with fixatives 
such as 4% glutaraldehyde or formaldehyde to allow safer handling during analysis, 
without disrupting the distinctive staining pattern. An example is provided by cell-
permeant, green-fluorescent DNA probe SYTO-10 and the cell-impermeant, red-fluorescent 
DNA probe ethidium homodimer-2 (Barnett et al., 2004; Poole et al., 1996). Using these two 
probes cells can be stained and fixed at various times during an experiment, and the results 
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can be analyzed several hours later. This method may be applied to viability assessment of 
any non-adherent cells, as well as trypsinized adherent cells. Tables 1, 2, and 4 summarize 
the main features of viability probes based on enzymatic activity and DNA labelling 
discussed above that may be considered to meet specific experimental requirements. 
Ethidium
homodimer-2
SYTO-Red
SYTO-10
7AAD
Propidium 
iodide
SYTOX-Red
SYTOX-Green
SYTOX-Blue
Probe
Blue
Blue
Blue
Blue
Blue
Red
Blue
UV-Violet
Excitation
line
Green
Red
Green
Red
Orange-Red
Red
Green
Blue
Fluorescence 
emission
NO
YES
YES
NO
NO
NO
NO
NO
Membrane 
Permeant
YESHigh
NOLow
YESLow
NOHigh
NOHigh
NOHigh
NOHigh
NOHigh
FixableDNA 
Affinity
 
Table 2. DNA probes used for viability assessment 
2.5 Two parameter assessment of viability through flow cytometry 
Identification of live and dead cells is often conducted with simultaneous use of two probes. 
The combination may include a cell-impermeant DNA probe and either a fluorogenic 
substrate or a cell-permeant DNA probe. It should be highlighted that viability may be also 
indicated by probes that have been designed to assess other cellular functions. For example 
generation of hydrogen peroxide and superoxide anion occurs in live cells due to normal 
function of mitochondrial electron transport chain and does not occur in dead cells. The 
superoxide anion probe dihydroethidine (HE) and the hydrogen-peroxide probe dihydro-
dichloro-fluoresceindiacetate (DH-DCFDA) will stain live cells red fluorescent and green 
fluorescent respectively (Eruslanov & Kusmartsev, 2010; Zanetti et al., 2005). Both probes 
may be appropriately combined with cell-impermeant DNA dyes to discriminate between 
live and dead cells. 
Similarly potentiometric dyes stain live cells with preserved mitochondrial membrane 
potential, but not dead or compromised live cells where the mitochondrial membrane 
potential has collapsed (Marchetti et al., 2004). Thus they may also be combined with cell-
impermeant DNA dyes to discriminate live and dead cells. For example, rhodamine 123 has 
been used in combination with propidium iodide for viability assessment with two-color 
flow cytomety (Darzynkiewicz et al., 1982). Metabolically active cells undergo normal 
oxidation-reduction reactions and thus can also reduce a variety of probes, providing a 
measure of cell viability and overall cell health (Callewaert et al., 1991; Radcliff et al., 1991). 
Resazurin and dodecylresazurin (C12-resazurin) have been extensively used as oxidation–
reduction indicators to detect viable cells (Czekanska, 2011). Reduction of resazurin yields 
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the red fluorescent product resorufin while C12-resazurin yields C12-resorufin which is 
better retained by single cells (Talbot et al., 2008). 
Again these probes may be combined with cell-impermeant DNA probes like SYTOX-green 
to discriminate live and dead cells with two color flow cytometry. 
2.6 Viability assessment with single-color fixable dyes 
In some experimental circumstances only one fluorescence channel may be dedicated to 
assessment of cell viability. In this case amine-reactive fluorescent dyes can be used to 
evaluate mammalian cell viability.  
In cells with compromised membranes, these dyes react with free amines both in the cell 
interior and on the cell surface, yielding intense fluorescent staining. In viable cells, the dyes 
only stain cell-surface amines, resulting in less intense fluorescence (Elrefaei et al., 2008). The 
difference in intensity between the live and dead cell populations is preserved following 
formaldehyde fixation, using conditions that inactivate pathogens (Burmeister et al., 2008). 
There are several options of fluorescence excitation (UV, violet, blue, and red lasers) and 
emission wavelength (blue, green, yellow, red).  
Far Red-665 nmRedLIVE/DEAD ®
Fixable Far Red
Blue-450 nmVioletFixable Viability 
Stain 450 ®
Far Red-660 nmRedeFluor® 660 
Green-506 nmBlueeFluor® 506
Blue-450 nmVioleteFluor® 450 
Red-615 nmRedLIVE/DEAD ®
Fixable Red
Green-520 nmBlueLIVE/DEAD ®
Fixable Green
Blue-450 nmVioletLIVE/DEAD ®
Fixable Violet
Yellow-575 nmVioletLIVE/DEAD ®
Fixable Yellow
Green-526 nmUVLIVE/DEAD ®
Fixable Aqua 
Blue-450 nmUVLIVE/DEAD® fixable 
Blue
Fluorescence 
emission
Excitation
line
Probe
 
Table 3. Fixable amine-reactive fluorescent probes used for single-color assessment of cell 
viability. The wavelengths indicated correspond to the emission peaks as specified by the 
probe manufacturer 
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2.7 Viability vs. apoptosis 
Most targeted cytotoxic drugs have been shown to induce apoptosis or other modes of 
programmed cell death, including autophagic cell death or programmed necrosis. These 
mechanisms of cell death are often contrasted to necrosis where a passive, sudden and 
uncontrolled disintegration of the cell occurs. Physiological consequences of apoptosis and 
passive necrosis are different, and thus it is important to determine the cell death 
phenotype. When assessed through flow cytometry, cells undergoing apoptosis or other 
forms of programmed cell death show a decrease in cell volume and forward light scatter 
(FSC), and an increase in side light scatter (SSC) mainly due to cytoplasmic and nuclear 
changes such as blebbing, and nuclear fragmentations (Dive et al., 1992; Pheng et al., 2000). 
In contrast necrosis often shows increased cell volume and FSC without changes in SSC 
(Healy et al., 1998). Viability assessment after cytotoxic drug exposure does not address the 
cell death phenotype, thus any kind of cell death phenotype may be induce by drug 
treatment including passive necrosis (Healy et al., 1998). However studies determining the 
median cytotoxic dose will require exposure to increasing doses from sub-lethal levels to the 
minimal doses approaching 100% cell death. In this scenario, programmed cell death 
phenotypes are more frequently observed than passive necrosis.  
OrangeGreenNOJO-PRO-1
OrangeGreenNOJOJO-1
RedRedNOBOBO-3
Far RedRedNOTOTO-3
RedRedNOYOYO-3
BlueUV-VioletNOBOBO-1
BlueUV-VioletNOPOPO-1
GreenBlueNOTO-PRO
GreenBlueNOTOTO
GreenBlueNOYOYO-1
Fluorescence 
emission
Excitation
line
Membrane 
Permeant
Probe
 
Table 4. Membrane–impermeant dimeric and monomeric cyanine dyes are nonfluorescent 
unless bound to nucleic acids and have extinction coefficients 10–20 times greater than that 
of DNA-bound propidium iodide 
2.8 FDA-PI staining and the "cell death pathway": Frequency distributions of graded 
and abrupt transitions 
When two fluorescent probes are used to determine the proportion of live and dead cells 
after exposure to cytotoxic drugs over an extended dose range data analysis would be better 
analyzed on a bivariate plot. 
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An example is the pair represented by FDA as an indicator of esterase activity in live cells 
and PI as an indicator of cell membrane damage (Fig. 1). In this case a bivariate plot of green 
fluorescence against red fluorescence will aid in determining the percentage of live and 
dead cells (Fig. 1A,C). In addition, the bivariate plot will provide useful data about the 
biological processes evaluated with FDA and PI.  
A concept frequently present in flow cytometry, particularly when analyzing bivariate plots, 
is the presence of graded transitions or abrupt changes (Shapiro, 2003). These patterns in 
bivariate distributions are determined by the underlying biological process that is being 
studied. For example damage of cell membrane allows staining by PI probe so that cells may 
be classified as dead with a permeable membrane or live having preserved selective 
permeability, depending on whether they are red fluorescent or not. Cells are observed to be 
bright stained or having no stain at all, but very rarely they are observed to have dim red 
fluorescence. Thus membrane damage and PI staining is an example of an abrupt transition 
or discrete process represented by membrane damage that produces a sudden change in the 
frequency distribution. This frequency distribution is symmetric, bell-shaped, and has low 
variability around the peak (Fig. 1C,E.). 
By contrast when analyzing drug-induced effects on esterase activity through green 
fluorescence we will observe a graded transition from bright fluorescence to dim 
fluorescence (Fig. 1C). Thus a graded biological process represented by progressively 
decreased esterase activity determines a skewed frequency distribution with higher 
variability around the peak (Fig. 1F). In this case there will be a higher probability of 
observing cells within any level of metabolic activity represented by the amount of green 
fluorescence: bright, intermediate and dim. Note also that cells with damaged membrane no 
longer retain fluorescein (very few events are seen in upper right quadrant, Fig. 1C).  
When analysis is restricted to live cells without damaged membrane (PI negative) it is more 
evident that the probability of finding live cells with low metabolic activity in the drug-
treated population decreases gradually (Fig. 1H). By contrast, when the analysis is restricted 
to cells without metabolic activity a narrow bell-shape distribution is observed meaning that 
the probability of finding cells with damaged membrane in cells without metabolic activity 
increases abruptly (Fig. 1G). When combined in a bivariate plot the gradual decrease in 
metabolic activity in live cells is observed as a continuous distribution or pathway, while the 
abrupt transition from membrane-impermeable to membrane-permeable is observed as a 
discrete transition to a main single cluster of PI-positive cells with very low or no metabolic 
activity (Fig. 1C). The probability of finding cells with low or no metabolic activity is very 
low as shown by the few cells in an intermediate position along this "death-pathway". 
Changes in FSC and SSC are also graded transitions and define a "death-pathway" in 
bivariate plots (Fig. 1D). Most cells having membrane damage have low FSC and high SSC, 
those cells without membrane damage and with metabolic activity have high FSC and low 
SSC, while intermediate positions may be occupied by either of these populations (Fig. 1D). 
Thus the death pathway defines a whole range of changes occurring in all four parameter 
FSC, SSC, FDA, and PI. However the main result is characterizing cells as either dead or 
alive and this difference is brought by PI staining and membrane damage. Thus applying 
quadrant analysis we would add the fraction of cells in both upper quadrants and the 
fraction of cells in the lower quadrants as live cells (Fig 1C). The remaining parameters will 
work as internal quality controls.  
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Fig. 1. (continues on next page) The FDA vs. PI bivariate plot and the cell death pathway. A. 
Sample of human U937 leukemic cells labelled with FDA and PI. Lower right quadrant 
shows that most cells (97.30%) have esterase enzymatic activity and preserved membrane 
permeability because they exclude PI staining. Only 1.43% of cells have PI staining without 
FDA fluorescence, while 1.05% are double positive indicating both enzymatic activity and 
damaged membrane. B. FSC-SSC profile of live cells is show in green and corresponds to the 
97.30% of cells shown in the lower right quadrant of panel A. The small amount of single PI 
positive (red) and double positive cells (blue) are also observed. C. Sample of human U937 
cells exposed to 5 μM sodium arsenite (AsNaO2) for 72h stained with FDA and PI showing 
a "slow" transition from high FDA fluorescence to low FDA fluorescence (green) and a 
further "abrupt" transition to a PI positive FDA negative cluster of dead cells (red). A 
minority of cells are double positive (blue). The whole transition is indicated with the black 
arrow. D. FSC vs. SSC plot of the sample shown in C. Green color represents FSC-SSC 
paired values only occupied by live cells (lower right quadrant shown in C), red color 
represents FSC-SSC paired values only occupied by dead cells (upper left quadrant in C), 
while yellow color represents FSC-SSC paired values occupied by both live and dead cells. 
The black arrow shows the graphical death pathway transition in the FSC SSC plot. The 
FSC-SSC values of the minority of double positive cells are shown in blue 
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Fig. 1. (continued) E. Frequency distribution of PI fluorescence corresponding to the sample 
shown in C and D. Note that positive and negative cell populations are bell-shaped, 
symmetrical, with low variability around the peaks, and well separated from each other F. 
Frequency distribution of FDA fluorescence of the same sample shown in C and D. The 
population of positive cells shows asymmetrical left-skewed distribution with great variability 
to the left of the peak. G. The sample shown in E with live cells excluded. The probability of 
finding positive cells with intermediate and dim PI fluorescence decreases abruptly to the 
left. H. The sample shown in F with dead cells excluded. The probability of finding positive 
cells with intermediate and dim FDA fluorescence decreases slowly to the left 
3. Building a cytotoxic dose response curve 
Theoretically, if a population of cells were homogenously sensitive to cell death induced by 
a certain drug there would be a single dose D at which 100% cell death would be observed 
(Casarett et al., 2008; Goodman et al., 2010). However in any given sample of drug-treated 
cells a random proportion of cells will die at doses lower or higher than D due to 
experimental and biological variability. This random divergence from D follows a Gaussian 
distribution (Fig. 2A,C).  
www.intechopen.com
 
Flow Cytometry – Recent Perspectives 
 
404 
A B
C D
0
0.25
0.5
0.75
1
2 4 6 8 10 12
D (dose, uM)
F
ra
c
ti
o
n
 o
f 
d
e
a
d
 c
e
ll
s
D=Dm
Dm=7uM
SD
0
0.1
0.2
0.3
0.4
0.5
2 4 6 8 10 12
D (dose, uM)
F
ra
c
ti
o
n
 o
f 
d
e
a
d
 c
e
ll
s
D=Dm
Dm=7uM
SD
0
0.25
0.5
0.75
1
2 4 6 8 10 12
D (dose, uM)
F
ra
c
ti
o
n
 o
f 
d
e
a
d
 c
e
ll
s
D=Dm
Dm=7uM
SD=1uM
SD=1.8uM
0
0.1
0.2
0.3
0.4
0.5
2 4 6 8 10 12
D (dose, uM)
F
ra
c
ti
o
n
 o
f 
d
e
a
d
 c
e
ll
s
D=Dm
SD=1uM
Dm=7uM
SD=1.8uM
 
Fig. 2. Quantal dose response model. A. Single cells will show differences on the minimal 
drug dose required to induce cell death. Dm is the most frequent minimal dose required to 
elicit cell death. Variations around this value have a normal distribution. In this particular 
example Dm is 7uM and the standard deviation (SD) is 1uM. B. Dm is the drug dose that is 
estimated to kill half of the cells in a sample. When running experiments exposing cells to 
incremental doses of a cytotoxic drug the fraction of dead cells observed will follow a 
normal cumulative function. C. Differences between two cytotoxic drugs in the variability 
observed around Dm. The drug represented by the dotted line has larger variability (SD=1.8 
uM) than the drug represented in full line (SD=1 uM). D. Increased variability around Dm is 
observed as a dose response curve with a smaller slope as shown by the dotted line of the 
cumulative normal distribution 
The median dose Dm represents a dose D where half of the cells are killed and half of the 
cells remain live (Fig. 2 B). However, as indicated by the bell shape of the Gaussian 
distribution many of the 50% of cells killed at a dose Dm may have required less than Dm to 
be killed. In fact as shown in figure 2A only a fraction of cells will require strictly a dose Dm 
(those in the bell peak), while a minority of cells will require a dose much lower than Dm to 
be killed (those in the left tail of the bell-shaped curve). If we conduct experiments 
evaluating the cytotoxic effect of increasing doses we will observe a sigmoid curve that 
follows a cumulative Gaussian frequency distribution (Fig. 2B). Doses lower than Dm will 
show decreased probability of cell death approaching 0% while doses higher than Dm will 
show increased probability of cell death approaching 100% (Fig. 2B). This model is known 
as quantal dose-response because it is based on the scoring of all members of a sample 
population for having or not having a certain condition at a given applied dose (Casarett et 
al., 2008). This is precisely what is done through flow cytometry assessing a sample on a cell 
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by cell basis for being dead or alive. Using flow cytometry we can measure the fraction of 
cells killed (fa) at a dose D with high accuracy and precision due to the large number of cells 
analyzed which ensures an extremely low standard error (SE). However, high accuracy and 
precision apply to a single sample and not to replicates. The source of variability between 
replicates will be both biological and experimental. For example cells overgrown in culture 
may respond with higher variability than cells in exponential growth when estimated from 
replicates. Similarly any problems around drug exposure or the staining procedure will add 
to the variability of replicates although the precision and accuracy of each sample 
determination will be very high due to the large amount of cells scored in each sample tube. 
Regarding calculation of the median cytotoxic dose Dm this replicates will have a critical 
impact on the statistical precision of the Dm estimate. 
3.1 Calculating the median dose: The median effect equation 
Cells cultured in vitro can be exposed to increasing doses of a cytotoxic drug during a 
certain time interval (e.g., 48h or 72h) to determine a median cytotoxic dose Dm. Several 
doses should be tested to extend over a dose range. The lower doses should induce a 
fraction of dead cells close to that of unexposed cells, while the higher doses should induce 
death values approaching 100% or achieve a plateau of maximal effect. In between these 
boundary doses the more intervals assessed the more precision we will get in the estimates. 
For example seven doses assessed in triplicate that yield cell death fractions between 5% and 
95% would be enough to obtain regression estimates with an adequate precision. The dose 
response sigmoidal curve can be fit to a two parameter logistic function of the type: 
 fa= 1 / [1+1/(D/Dm)m] (1) 
where D is the dose, Dm is the dose required to achieve the median cytotoxic effect, fa is the 
fraction of dead cells, and m is a measurement of the sigmoidicity of the curve. When m=1 
the dose-effect curve is hyperbolic, when m>1 the curve is sigmoidal, while m<1 indicates a 
negative sigmoidal shape (Fig. 3A). 
To estimate Dm and m the median effect equation is written as:  
 fa/(1-fa) = (D/Dm)m (2) 
The factor (1-fa) is the fraction of live cells. Applying a log transformation the following 
linear function is obtained:  
 log (fa/(1-fa) = m . log (D) - m . log (Dm) (3) 
Thus plotting log values of experimental doses against log values of the ratio of dead/live 
cells will show a linear trend that is often referred to as median effect plot (Fig. 3B). 
This is a linear function of the type y= m.x + b, where y=fa/(1-fa), x=log(D), and b=-m.log 
(Dm). A linear regression can be applied to these data to obtain estimates for m and Dm. 
The m coefficient can be readily determined by the slope of the regression, and Dm is 
derived from the estimate of the intercept -m.log(Dm).  
The squared correlation coefficient or R2 value is an estimate of the precision of the overall 
regression (Fig. 3B). In this particular application to data representing cell death vs. dose of 
cytotoxic drug, R2 is affected mainly by the scattering of replicate values, which in turn 
www.intechopen.com
 
Flow Cytometry – Recent Perspectives 
 
406 
depend on the experimental and biological variability, and also on the number of sample 
doses in between the lowest and highest effect values. The standard error (SE) of m and the 
intercept can also be obtained from regression analysis to get a 95% confidence interval 
around log(Dm). The formula for manual calculation is rather complicated and involves 
computing SE(log(D)) when D=Dm (shown in eq. 14, Table 5) but may be obtained using 
any software that implements this calculation such as Calcusyn or Compusyn (Bijnsdorp et 
al., 2011; Ikeda et al., 2011; Ramachandran et al., 2010). 
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Fig. 3. Median effect plot. A. The two parameter dose-response sigmoidal curve for a 
particular example with Dm=7uM and m=5. B. Algebraic and log transformation to obtain a 
linear function. A linear regression can be applied to experimental data in order to obtain 
estimates of the two parameters Dm and m. The squared correlation coefficient R2 is a 
measure of the overall precision of the linear regression and thus the Dm and m estimates 
3.2 Threshold, median dose and maximal efficacy 
Analysis of the dose-effect plot can be informative about threshold values and maximal 
efficacy values.  
In practice the threshold value will be the minimal dose where the fraction of dead cells is 
higher than that of untreated cells. The maximal efficacy would be the fraction of dead cells 
where the sigmoidal curve approaches a plateau. Quite often the maximal efficacy 
approaches 100%. However a cell population may exhibit a differential response and a 
fraction of cells may require quite larger doses. In these cases the maximal efficacy will be 
much less than 100%. 
3.3 Comparing two drugs 
To compare two drugs and evaluate whether combination results in synergy or not a first 
step is to calculate Dm for the two drugs. Thus, the same approach described above should 
be applied to the second drug. The procedure will include evaluating several doses in 
replicates with the same exposure time interval as the first drug, obtaining data to create a 
median effect plot and estimating m and Dm by linear regression (Chang et al., 1987; Chou 
& Talalay, 1984; Sugiyama et al., 1998).  
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Results from assessment of the two drugs can be analyzed together in a combined median 
effect plot where log doses (in molar units) are depicted against log (fa/1-fa). In this plot the 
relative potency of the two drugs can be easily appreciated (Fig. 4A). A drug a is said to be 
more potent than a second drug b regarding the cytotoxic effect when less dose of dug a is 
needed to achieve the same cytotoxic effect with drug b on a molar basis. In addition when 
the slopes of the two drugs are different it suggests that the drugs have different 
mechanisms to induce cytotoxicity. 
The dose effect equation can be re-written to calculate the dose required to induce a given 
cytotoxic effect: 
 D=Dm (fa/(1-fa))1/m  (4) 
For example the effective cytotoxic dose 50% (EC50) is the dose D that is estimated to kill 
50% of the cells. In this case fa=0.5 and EC50 is coincident with the median dose Dm. 
Similarly EC25 is the dose D that is estimated to kill 25% of the cells. 
3.3.1 Assessing the combined effect of two drugs under fixed molar ratio  
Once obtained the dose-response curve for two drugs a and b, a third experiment with 
combination of a + b will be needed to determine if the interaction of these drugs is additive, 
synergic or antagonistic.  
Assuming that the drug b is less potent than the drug a, fixed molar ratio could be used in 
the combination based on the relative potency EC50(a)/EC50(b). For example if EC50(a) is 
10μM and EC50(b) is 30μM, the molar ratio of the combination would be 1/3. An empirical 
approach is to start the combination experiment with a combination of a+b calculated as  
 EC50(a+b)=10{[log(EC50(a))+log(EC50(b))]/2} (5) 
In this example this estimated value would be 17.3 μM. Assuming the fixed molar ratio 1/3 
this combination would have 4.3μM of drug a and 13.0 μM of drug b.  
Next we should treat this combination as a new drug a+b and evaluate several doses above 
and below 17.3μM in replicates to span a dose range of the combination. Thus, we will 
experimentally obtain a new data set of doses and cytotoxic effects that we should evaluate 
by the same procedure with the median effect plot, and conduct a linear regression to obtain 
estimates for m and Dm with the combination of a+b. 
In particular we will obtain an effect-dose equation as shown above (eq. 4) to determine the 
dose of the combination a+b to achieve a desired cytotoxic effect level (EC) 
 D= Dma+b (fa/(1-fa)) 1/ma+b (6) 
For example applying (eq.5) EC50 (a+b) will be equal to the median dose estimated from the 
regression in the combined experiment (Dma+b) 
3.4 Graphical analysis 
A first approach is to plot this result together with results of single drug effects to depict 
some relevant information (Pegram et al., 1999). When the combined-drug curve lies in a  
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midpoint between the two single drug curves it suggests an additive effect (Fig. 4A). It 
indicates that the potency of the combined drugs is at an intermediate point between the 
potency of each drug. When the combined drug curve is shifted to the left it would be closer 
to the more potent single drug and thus suggests synergism (Fig. 1B). On the other side 
when the combined drug curve is shifted to the right and closer to the low potency drug it is 
suggestive of antagonism (Fig. 1C). Another hint that could aid in generating hypothesis is 
the curve shape and particularly the slope. The variability around Dm is represented by the 
standard deviation (SD) of the Gaussian distribution underlying the quantal dose-response 
model discussed above. A large SD is in accordance with a flat curve while a small SD is in 
accordance with a steep curve (Fig. 2C,D). This variability has a biological significance and 
two drugs having different mechanisms of inducing cell death in a certain cell line may have 
different slopes. 
3.5 Calculating the combination index (CI) 
The graphical analysis gives some clues about what kind of interaction results from the 
combination of drugs a and b and depicts useful information but is less conclusive in 
quantitative terms. A more thorough conclusion can be derived from computing the 
combination index for each cytotoxic effect level (Chou, 2008; 2010). Computing the 
combination index (CI) for each effect level provides an answer to what kind of interaction 
occurs between drug a and drug b throughout the whole dose range. 
The combination index method takes data provided by single and combined dose-effect 
equations to provide an estimate at the whole range of cytotoxic effects. The combination 
index is defined for a given effect level i by the following equation: 
 CI (i) = Dac(i) /Das(i) +Dbc(i) /Dbs(i) + α Dac(i) . Dbc(i) / Das(i) . Dbs(i) (7) 
Where Dac(i) and Dbc(i) are the doses of drugs a and b respectively required in the 
combination a+b to produce an effect level i. 
Das(i) and Dbs(i) are the doses of drug a and b respectively, required to produce an effect 
level i when used as single drugs. For any level i, these values are obtained from the three 
dose response curves defined by (eq. 4) (two single and one combined) obtained with 
parameters Dm and m that in turn were obtained from regression analysis with (eq.3) 
applied to experimental data. It is often assumed the conservative criteria that cytotoxic 
drugs are mutually non exclusive and α=1. If the three lines are strictly parallel and both 
drugs have a similar molecular target it could be assumed that they are mutually exclusive 
and in that case α=0. If the fixed molar ratio of drug a and b in the combined treatment is 
p/q, then for an effect level i: 
 Das(i)=Dma (fa(i)/(1-fa(i)))1/ma (8) 
 Dbs(i)=Dmb (fa(i)/(1-fa(i)))1/mb (9) 
 Dac(i)=p/(p+q) Dma+b (fa(i)/(1-fa(i)))1/ma+b (10) 
 Dbc(i)=q/(p+q) Dma+b (fa(i)/(1-fa(i)))1/ma+b (11) 
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Where fa(i) is the fraction of dead cells at effect level i, Dma and ma are the median dose and 
the slope estimated for drug a, Dmb and mb are the median dose and the slope estimated for 
drug b, and Dma+b and ma+b are the median dose and the slope estimated for the combined 
treatment with drugs a and b. Thus the combination index is calculated for any effect level 
above 0 and below 1.  
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Fig. 4. Drug interaction and median effect plot. A. In this example experimental values are 
represented by circles and linear regression is applied to obtain estimates for Dm and m. 
Experimental values obtained for a drug a are shown in black circles. The values of Dm and m 
for drug a were 10 μM and and 3.0 respectively. Experimental values for a less potent drug b 
are shown in open circles. The values of Dm and m for drug a were 30 uM and and 3.0 
respectively. A combined experiment was run with a+b with a constant mass ratio of 1/3 
based on EC50(a)/EC50(b) and assuming that under additive effect 
EC50(a+b)=10{[log(EC50(a))+log(EC50(b))]/2}. Experimental values for the combination are 
shown in grey circles. The values of Dm and m for the combination a+b were 17.0 uM and 
and 3.0 respectively. In this example drugs a and b have an additive interaction and the 
median effect plot of the combination lies in a mid position between the lines corresponding 
to the single drugs. B. The same experiment shown in A, but in this case the drugs a and b 
have synergic effect. The values of Dm and m for the combination a+b were 14.0 uM and 
and 3.0 respectively. The median effect plot of the combination is shifted towards the drug 
a, which has the highest potency. C. The same experiment shown in A, but in this example 
the drugs a and b have antagonistic effect. The values of Dm and m for the combination a+b 
were 24.4 uM and and 2.9 respectively. The median effect plot of the combination in this 
case is shifted towards the drug b which has the lowest potency 
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Additive Synergic Antagonistic
Single 
drug a
Single 
drug b
Combined drugs 
a+b
Combined drugs 
a+b
Combined drugs 
a+b
Dm (uM) 
#(1) 10 30 17 14 24.4
m 
#(1) 3 3 3 3 3
fa(i) 0.5
Das(i) 
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Dbs(i) 
#(3) 30
Dac(i) 
#(4) 4.25 3.5 6.1
Dbc(i) 
#(5) 12.75 10.5 18.3
p/(p+q) 
#(6) 0.25 0.25 0.25
q/(p+q) 
#(6) 0.75 0.75 0.75
CI (i) 
#(7) 1.03 0.82 1.59
Three alternative results of the experimental 
assay with combination a +b ( considering α=1, 
mutually non-exclusive condition)
#
 
(1)
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(2)
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(3) Dbs(i)=Dmb (fa(i)/(1-fa(i)))
1/m
b
#
 
(4) Dac(i)=p/(p+q) Dma+b (fa(i)/(1-fa(i)))
1/m
a+b
#
 
(5) Dbc(i)=q/(p+q) Dma+b (fa(i)/(1-fa(i)))
1/m
a+b
#
 
(6) Molar ratio p/q = Dm(a) /Dm(b) = 10/30 = 1/3
#
 
(7)
Obtained from linear regression of experimental data
Das(i)=Dma (fa(i)/(1-fa(i)))
1/m
a
CI(i) = Dac(i) /Das(i) +Dbc(i) /Dbs(i) + α Dac(i) . Dbc(i) / Das(i) . Dbs(i)
SE(D) = 1/2 . {10 
[log(D)+SE(log(D)]
-10 
[log(D)-SE(log(D)]
}                           (eq. 13)
where b=-m.log(Dm) 
SE(CI(i))={{ Dac(i)/ Das(i) . [SE(Dac(i)/ Dac(i)+ SE(Das(i)/ Das(i)]}
2
 +{ Dbc(i)/ Dbs(i) . 
[SE(Dbc(i)/ Dbc(i)+ SE(Dbs(i)/ Dbs(i)]}
2
}
1/2
                      (eq. 12)
SE(log (D)) ={log(D) . [SE(b)/log(fa/(1-fa)-b]
2
+[SE(m)/m]
 2
+2[-(logD)
1/2
 . SE(m)/SE/(b)] . 
SE(b)/b . SE(m)/m}
1/2                                                              
(eq. 14)
A 95% confidence interval around D in general and around Dm in particular, can be 
computed using the formulas for standard error (SE, eq. 13 and eq. 14). 
A 95% confidence interval around CI at any effect level i can be computed from the 
standard error formulas presented in eq. 12, 13, and 14.
 
Table 5. CI calculation between two drugs a and b at the 50% effect level under three 
alternative conditions: additive, synergic, antagonistic. To obtain CI as a function of the 
effect level i, the calculation has to be repeated for each arbitrary level i between 0 and 1. A 
95% confidence interval around D in general and around Dm in particular, can be computed 
using the formulas for standard error (SE, eq. 13 and eq. 14). A 95% confidence interval 
around CI at any effect level i can be computed from the standard error formulas presented 
in eq. 12, 13 and 14 
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Table 5 summarizes a manual calculation of CI of two drugs a and b using these formulas 
for the 50% effect level under three hypothetical results: additive, synergic or antagonistic 
effect.  
The same calculation can be applied to any effect level to plot CI as a function of effect level. 
When the interaction is additive CI =1. In this case it can be interpreted that one of the drugs 
(the less potent one, i.e. drug b in the example) is acting as though it is merely a diluted 
form of the other (drug a in the example). When CI<1 the combination of a+b is synergic 
while CI>1 indicates antagonism. Synergy, implies that the combination of the two drugs 
achieves a cytotoxic effect greater than that expected by the simple addition of the effects of 
the drugs a and b, while antagonism achieves a cytotoxic effect lower than that expected by 
additive effects of drugs a and b. 
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Fig. 5. Drug interaction and CI calculation. A. Only rarely the combination index obtained is 
constant for all effect levels. Here it is shown how different values of the slope m obtained 
through linear regression in the combination experiment (a+b) would affect the shape of the 
curve representing the CI as a function of the effect level. Similarly, differences between the 
slopes obtained for drugs a and b through the single drug experiments will contribute to the 
uneven shape of the CI function. Note that depending on the effect level the interaction a+b 
with m=1.8 would be synergism, additive or antagonism at EC25. EC50, and EC75 
respectively (arrows). B. Results of CI calculation for the example where a+b results in 
synergism considering m=4 in the regression of the combined-drug experiment. C. Results 
of CI calculation for the example where a+b results in antagonism considering m=2.5 in the 
regression of the combined-drug experiment. D. 95% confidence level intervals around CI, 
using an algebraic approximation (eq. 12, Table 5) in an example where combination of a+b 
is synergic 
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The horizontal line corresponding to CI(i)=1, where i is any effect level in the interval (0,1), 
is often call the additive effect line. A combination of drugs a and b may result in CI values 
above or below the additive line at different effect levels. Thus, the CI as a function of effect 
level is not constant or linear and it may be decreasing or increasing (Fig 5A). If data from 
the combination experiment in the example of figure 4A resulted in ma+b=5 or ma+b=1.8, even 
still with Dma+b =17 the CI line would be inclined downwards or upwards respectively (Fig. 
5A). Only at effect levels close to EC50 the result would be strictly additive. An important 
conclusion is that for some drug combinations, experiments conducted at different single 
dose-effect levels may yield opposing results. For example if the combination a+b with 
m=1.8 shown in figure 5A were experimentally evaluated only at effect level 0.25 the single 
dose analysis would conclude on synergism. However if it were evaluated at effect level 
0.75 it would conclude on antagonism (Fig. 5A). This exemplifies why the assessment of 
combination index over the whole dose range will show all kinds of interactions that may 
result from combination at different effect levels. 
Computing a standard error of CI allows plotting confidence intervals at all effect levels 
providing a further assurance over the computation. A 95% confidence interval will indicate 
that if we repeat the experiment 100 times, 95 out 100 times the CI would be within this 
interval. For example, observing whether or not confidence limits are above or below the 
additive line will allow concluding with further statistical support on antagonism or 
synergism respectively. Computation of the standard error of CI and confidence intervals at 
all levels should be better obtained through specialized software such as Calcusyn or 
Compusyn (Bijnsdorp et al., 2011; Chou, 2010). It may also require approaches such as 
Monte Carlo simulation based on the estimated parameter for m and Dm in single and 
combined equations. 
4. Concluding remarks 
A thorough assessment of drug interaction is an essential step in targeted combined 
therapy. The new targeted agents are seldom useful as single agents but may be effective 
when used in specific combinations. The median effect and combination index calculation 
are well founded methods traditionally used in pharmacological and toxicological studies. 
Since new cytotoxic drugs target mechanisms eliciting cell death, biomarkers related to 
viability assessment are preferred to biomarkers of cell proliferation. Flow cytometry is an 
ideal technology to provide massive data from cell death biomarkers to build dose response 
curves of cytotoxic effect. When these data is further used to determine the combination 
index a full characterization of drug interaction over the cytotoxic effect is obtained at all 
effect levels. This approach can be applied to tumor cell lines in preclinical studies and also 
in patient-derived tumor cells, thus providing useful information as prospective indicators 
of the potential therapeutic response to combined-drug antitumor treatment. 
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